JP2025081512A5 - - Google Patents
Info
- Publication number
- JP2025081512A5 JP2025081512A5 JP2025024834A JP2025024834A JP2025081512A5 JP 2025081512 A5 JP2025081512 A5 JP 2025081512A5 JP 2025024834 A JP2025024834 A JP 2025024834A JP 2025024834 A JP2025024834 A JP 2025024834A JP 2025081512 A5 JP2025081512 A5 JP 2025081512A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- cdr
- domain
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824080P | 2019-03-26 | 2019-03-26 | |
| US62/824,080 | 2019-03-26 | ||
| US201962931103P | 2019-11-05 | 2019-11-05 | |
| US62/931,103 | 2019-11-05 | ||
| US202062969569P | 2020-02-03 | 2020-02-03 | |
| US62/969,569 | 2020-02-03 | ||
| JP2021557377A JP2022527081A (ja) | 2019-03-26 | 2020-03-26 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
| PCT/US2020/025069 WO2020198531A2 (en) | 2019-03-26 | 2020-03-26 | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557377A Division JP2022527081A (ja) | 2019-03-26 | 2020-03-26 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025081512A JP2025081512A (ja) | 2025-05-27 |
| JP2025081512A5 true JP2025081512A5 (enExample) | 2025-07-31 |
Family
ID=72610137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557377A Pending JP2022527081A (ja) | 2019-03-26 | 2020-03-26 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
| JP2025024834A Pending JP2025081512A (ja) | 2019-03-26 | 2025-02-19 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557377A Pending JP2022527081A (ja) | 2019-03-26 | 2020-03-26 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230312708A1 (enExample) |
| EP (1) | EP3953372A4 (enExample) |
| JP (2) | JP2022527081A (enExample) |
| KR (1) | KR20210143804A (enExample) |
| CN (1) | CN113710688A (enExample) |
| AU (1) | AU2020248448B2 (enExample) |
| CA (1) | CA3134465A1 (enExample) |
| IL (1) | IL286618A (enExample) |
| MX (1) | MX2021011494A (enExample) |
| SG (1) | SG11202110131SA (enExample) |
| WO (1) | WO2020198531A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116940378A (zh) * | 2021-02-01 | 2023-10-24 | 加利福尼亚大学董事会 | 神经内分泌癌的治疗 |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| KR20250044188A (ko) | 2022-05-12 | 2025-03-31 | 하이난 심시어 자이밍 파마슈티컬 컴퍼니 리미티드 | 캄프토테신계 유도체 및 리간드-약물 접합체 |
| US20240092941A1 (en) * | 2022-07-11 | 2024-03-21 | Fred Hutchinson Cancer Center | Single-domain antibodies that bind ror1 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025079987A2 (ko) * | 2023-10-10 | 2025-04-17 | 서울대학교산학협력단 | 키메라 항원 수용체를 발현하는 자연 살해 세포를 이용한 종양 미세환경의 주피세포를 표적하는 항암 세포 치료 기법 및 치료 효능 평가를 위한 종양 미세환경 오가노이드 모델 제작 기술 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US9758591B2 (en) * | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
| KR102048855B1 (ko) * | 2014-07-29 | 2019-11-26 | 셀렉티스 | 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체 |
| US20170333480A1 (en) * | 2014-11-05 | 2017-11-23 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| AU2016206457B2 (en) * | 2015-01-16 | 2021-11-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ROR1 |
| KR20180111870A (ko) * | 2016-02-25 | 2018-10-11 | 셀 메디카 스위처란트 아게 | Pd-l1에 대한 결합 성분 |
| MY200337A (en) * | 2016-10-07 | 2023-12-20 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain |
| CN108424458A (zh) * | 2017-02-13 | 2018-08-21 | 上海恒润达生生物科技有限公司 | 靶向ny-eso-1的嵌合抗原受体及其用途 |
| AU2018289581C1 (en) * | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| CN116018353A (zh) * | 2019-11-18 | 2023-04-25 | 加利福尼亚大学董事会 | 抗ror-2抗体和使用方法 |
-
2020
- 2020-03-26 CN CN202080028702.4A patent/CN113710688A/zh active Pending
- 2020-03-26 EP EP20778519.7A patent/EP3953372A4/en active Pending
- 2020-03-26 JP JP2021557377A patent/JP2022527081A/ja active Pending
- 2020-03-26 MX MX2021011494A patent/MX2021011494A/es unknown
- 2020-03-26 US US17/598,200 patent/US20230312708A1/en active Pending
- 2020-03-26 KR KR1020217032699A patent/KR20210143804A/ko not_active Ceased
- 2020-03-26 CA CA3134465A patent/CA3134465A1/en active Pending
- 2020-03-26 WO PCT/US2020/025069 patent/WO2020198531A2/en not_active Ceased
- 2020-03-26 SG SG11202110131SA patent/SG11202110131SA/en unknown
- 2020-03-26 AU AU2020248448A patent/AU2020248448B2/en active Active
-
2021
- 2021-09-23 IL IL286618A patent/IL286618A/en unknown
-
2025
- 2025-02-19 JP JP2025024834A patent/JP2025081512A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025081512A5 (enExample) | ||
| JP7660382B2 (ja) | 多様な多重抗原のターゲティングのための汎用的キメラ抗原受容体を発現する免疫細胞および該免疫細胞の製造方法ならびに該免疫細胞の、癌、感染症および自己免疫疾患の治療のための使用 | |
| CN113234682B (zh) | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 | |
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2020115876A (ja) | Ｐｄ−ｌ１に対するヒト抗体 | |
| JP2020096630A5 (enExample) | ||
| JP7288503B2 (ja) | 改変された抗ｃｄ１９ ｃａｒ－ｔ細胞 | |
| FI3703750T3 (fi) | B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja | |
| JP2020022456A5 (enExample) | ||
| AU2017223846A1 (en) | Modified cells for immunotherapy | |
| JP2017507900A5 (enExample) | ||
| CN105384825A (zh) | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 | |
| EP3865513A1 (en) | Anti-cd19/anti-cd3 bispecific antibody, t cells secreting the same, method of preparation and use thereof | |
| Rosenzweig et al. | Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis | |
| JP2019536469A5 (enExample) | ||
| EP3819309A1 (en) | Hla-g specific chimeric antigen receptor, nucleic acid, hla-g specific chimeric antigen receptor expression plasmid, hla-g specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer | |
| JPWO2020198531A5 (enExample) | ||
| KR20210060355A (ko) | 항-CD300c 단클론 항체를 포함하는 암 예방 또는 치료용 조성물 | |
| EP3733708A1 (en) | Immune checkpoint molecule inhibitor | |
| JPWO2019241685A5 (enExample) | ||
| WO2022086620A1 (en) | Psma-targeted immunotherapies for cancers | |
| US20250161358A1 (en) | Modified immune effector cells and uses thereof | |
| WO2022178163A2 (en) | Antibody-derived t cell activating technologies | |
| Holzinger et al. | CARs on the highway: chimeric antigen receptor modified T cells for the adoptive cell therapy of malignant diseases |